2024
Deletion of miR‐33, a regulator of the ABCA1–APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice
Tate M, Wijeratne H, Kim B, Philtjens S, You Y, Lee D, Gutierrez D, Sharify D, Wells M, Perez‐Cardelo M, Doud E, Fernandez‐Hernando C, Lasagna‐Reeves C, Mosley A, Kim J. Deletion of miR‐33, a regulator of the ABCA1–APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice. Alzheimer's & Dementia 2024, 20: 7805-7818. PMID: 39345217, PMCID: PMC11567857, DOI: 10.1002/alz.14243.Peer-Reviewed Original ResearchAmyloid-betaAlzheimer's diseaseMicroglial migrationAmyloid mouse modelMiR-33Multi-omics studiesABCA1 levelsPotential drug targetsIncreased ABCA1 protein levelsMicroRNA-33ApoE lipidationProteomic changesRNA sequencingMulti-OmicsNeuropathological phenotypeAmyloid pathologyInhibition of miR-33APP/PS1 micePhagocytosis in vitroRare variantsApolipoprotein EDrug targetsABCA1 protein levelsAmyloidPlaque deposition
2011
Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis
Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, Rayner AJ, Chang AN, Suarez Y, Fernandez-Hernando C, Fisher EA, Moore KJ. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. Journal Of Clinical Investigation 2011, 121: 2921-2931. PMID: 21646721, PMCID: PMC3223840, DOI: 10.1172/jci57275.Peer-Reviewed Original ResearchConceptsABC transporter A1HDL levelsRegression of atherosclerosisCholesterol transportMiR-33MiR-33 inhibitionAtherosclerotic vascular diseasePlasma HDL levelsInflammatory gene expressionReverse cholesterol transportABCA1 levelsAtherosclerosis regressionVascular diseasePlaque macrophagesPlaque stabilityABCA1 expressionAtherosclerotic plaquesMice promotesProtective roleLipid metabolismLDL receptorClinical therapyPlaque sizeAtherosclerosisSREBF2 gene
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply